Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Frits Van Rhee to Clinical Trials as Topic

This is a "connection" page, showing publications Frits Van Rhee has written about Clinical Trials as Topic.

 
Connection Strength
  
 
 
1.458
  
  1. Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, van Rhee F. Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms. JAMA Netw Open. 2022 04 01; 5(4):e228161.
    View in: PubMed
    Score: 0.674
  2. Alqazaqi R, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy J, Zhan F, Tricot G, van Rhee F, Al Hadidi S. Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma. JAMA Netw Open. 2022 08 01; 5(8):e2228877.
    View in: PubMed
    Score: 0.173
  3. van Rhee F, Voorhees P, Dispenzieri A, Foss? A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018 11 15; 132(20):2115-2124.
    View in: PubMed
    Score: 0.132
  4. Thanendrarajan S, Davies FE, Morgan GJ, Schinke C, Mathur P, Heuck CJ, Zangari M, Epstein J, Yaccoby S, Weinhold N, Barlogie B, van Rhee F. Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going? Immunotherapy. 2016; 8(3):367-84.
    View in: PubMed
    Score: 0.110
  5. Liu YC, Stone K, van Rhee F. Siltuximab for multicentric Castleman disease. Expert Rev Hematol. 2014 Oct; 7(5):545-57.
    View in: PubMed
    Score: 0.099
  6. van Rhee F, Giralt S, Barlogie B. The future of autologous stem cell transplantation in myeloma. Blood. 2014 Jul 17; 124(3):328-33.
    View in: PubMed
    Score: 0.098
  7. Szmania S, Tricot G, van Rhee F. NY-ESO-1 immunotherapy for multiple myeloma. Leuk Lymphoma. 2006 Oct; 47(10):2037-48.
    View in: PubMed
    Score: 0.058
  8. Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J. Curing myeloma at last: defining criteria and providing the evidence. Blood. 2014 Nov 13; 124(20):3043-51.
    View in: PubMed
    Score: 0.025
  9. Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N, Brown T, Bartel T, Anaissie E, van Rhee F, Barlogie B. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood. 2013 Mar 07; 121(10):1819-23.
    View in: PubMed
    Score: 0.022
  10. Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BG, Harousseau JL. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol. 2010 Mar 01; 28(7):1209-14.
    View in: PubMed
    Score: 0.018
  11. Nair B, Shaughnessy JD, Zhou Y, Astrid-Cartron M, Qu P, van Rhee F, Anaissie E, Alsayed Y, Waheed S, Hollmig K, Szymonifka J, Petty N, Hoering A, Barlogie B. Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival. Blood. 2009 Jun 25; 113(26):6572-5.
    View in: PubMed
    Score: 0.017
  12. Barlogie B, Haessler J, Pineda-Roman M, Anaissie E, van Rhee F, Kiwan E, Steward D, Gurley J, Jenkins B, Crowley J. Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma: an important variable to be considered in clinical trial designs. Cancer. 2008 Jun 15; 112(12):2720-5.
    View in: PubMed
    Score: 0.016
  13. Barlogie B, Anaissie E, van Rhee F, Pineda-Roman M, Zangari M, Shaughnessy J, Epstein J, Crowley J. The Arkansas approach to therapy of patients with multiple myeloma. Best Pract Res Clin Haematol. 2007 Dec; 20(4):761-81.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.